Tag: equity
-
Spin-Off Companies to Develop Chronic Disease Therapies
Two new spin-off enterprises are being created to develop gut-based treatments for chronic diseases using technologies from synthetic biology company Intrexon Corporation.
-
Computational Drug Discovery Company Launches
A new enterprise, Relay Therapeutics, is being formed for computer-driven discovery of new drugs based on the movements and interactions of protein molecules.
-
Nanoparticle Therapy Start-Up Gains $4M in Early Funds
A start-up enterprise developing treatments for autoimmune disorders using protein-laden nanoparticles is raising $4 million in its first venture funding round.
-
Biopharm Company Raising $40 Million in IPO
Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering.
-
Amgen, Advaxis Partner on Personal Cancer Immunotherapy
Biological drug maker Amgen is licensing precision immunotherapy technology from Advaxis Inc. to develop treatments for cancer.
-
Univ. Spin-Off Develops New Cybersecurity Paradigm
A start-up enterprise from a university is developing a simplified cybersecurity infrastructure for businesses, and raised $2 million in its first funding round
-
Genetic Disease Biotech Gains $55M in Early Funds
A biotechnology start-up developing therapies for genetic diseases through regulation of genetic processes is raising $55 million in its first venture round.
-
Nanotech Imaging Start-Up Raises $3M in Seed Financing
A spin-off enterprise from University of California-Berkeley, developing an imaging technology with magnetic nanoparticles, is raising $3 million in funding.
-
Protein Biotech Lands $51.5M in First Venture Round
A spin-off enterprise from Harvard developing therapies that block signaling proteins causing disease is raising $51.5 million its first venture funding round.
-
Animal-Free Leather Company Gains $40M in Venture Funds
A company making leather for consumer goods with tissue engineering and gene-editing from living cells is raising $40 million in its second venture round.